David J Adelstein
Overview
Explore the profile of David J Adelstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
116
Citations
2766
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koyuncu C, Nag R, Lu C, Corredor G, Viswanathan V, Sandulache V, et al.
Cancer
. 2022 Sep;
128(21):3831-3842.
PMID: 36066461
Background: Understanding biological differences between different racial groups of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) patients, who have differences in terms of incidence, survival, and tumor morphology, can...
2.
Smile T, Reddy C, Matia B, Fleming C, Domb C, Geiger J, et al.
Anticancer Res
. 2022 Jul;
42(8):3845-3852.
PMID: 35896238
Background/aim: Definitive treatment for locally advanced head and neck squamous cell carcinoma (LAHNSCC) is often compromised in older adults due to concerns about potential treatment toxicity intolerance. We reviewed our...
3.
Lee M, Lee J, Stock S, Belfiglio M, Matia B, Koyfman S, et al.
Head Neck
. 2022 Jul;
44(10):2220-2227.
PMID: 35801556
Background: We sought to determine whether detection of cartilage invasion (CI) by computed tomography predicts oncologic outcomes after primary total laryngectomy. Methods: Retrospective cohort study comparing oncologic outcomes between radiologic...
4.
Lee M, Belfiglio M, Zeng J, Fleming C, Koyfman S, Joshi N, et al.
Laryngoscope
. 2022 Jun;
133(5):1122-1131.
PMID: 35754153
Objective: Organ preservation (OP) treatment for advanced laryngeal cancer has increased compared to primary total laryngectomy. Our study compares oncologic and functional outcomes between these approaches. Study Design: Retrospective cohort...
5.
A phase I/II trial of concurrent immunotherapy with chemoradiation in locally advanced larynx cancer
Frankart A, Sadraei N, Huth B, Redmond K, Barrett W, Kurtzweil N, et al.
Laryngoscope Investig Otolaryngol
. 2022 Apr;
7(2):437-443.
PMID: 35434343
Objectives: Cisplatin-based chemoradiation is an established organ-preserving strategy for locally advanced laryngeal cancer, but long-term survival remains suboptimal. Immunotherapy has been studied in the metastatic and unresectable recurrent settings. However,...
6.
I Ghanem A, Woody N, Schymick M, Joshi N, Geiger J, Tsai C, et al.
Oral Oncol
. 2022 Feb;
126:105781.
PMID: 35183910
Objectives: To explore the influence of treatment package time(TPT) in high-risk oral cavity squamous cell carcinoma(OCSCC) receiving adjuvant radiotherapy with concurrent chemotherapy(CRT). Materials And Methods: We queried our multi-institutional OCSCC...
7.
Corredor G, Toro P, Koyuncu C, Lu C, Buzzy C, Bera K, et al.
J Natl Cancer Inst
. 2021 Dec;
114(4):609-617.
PMID: 34850048
Background: Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) has excellent control rates compared to nonvirally associated OPSCC. Multiple trials are actively testing whether de-escalation of treatment intensity for these...
8.
Babar A, Woody N, I Ghanem A, Tsai J, Dunlap N, Schymick M, et al.
Curr Oncol
. 2021 Jul;
28(4):2409-2419.
PMID: 34209302
Adjuvant chemoradiation (CRT), with high-dose cisplatin remains standard treatment for oral cavity squamous cell carcinoma (OCSCC) with high-risk pathologic features. We evaluated outcomes associated with different cisplatin dosing and schedules,...
9.
Koyuncu C, Lu C, Bera K, Zhang Z, Xu J, Toro P, et al.
J Clin Invest
. 2021 Mar;
131(8).
PMID: 33651718
BACKGROUNDPatients with p16+ oropharyngeal squamous cell carcinoma (OPSCC) are potentially cured with definitive treatment. However, there are currently no reliable biomarkers of treatment failure for p16+ OPSCC. Pathologist-based visual assessment...
10.
Smile T, Xiong D, Varra V, Winter I, Beal B, Gastman B, et al.
Anticancer Res
. 2021 Jan;
41(1):289-295.
PMID: 33419823
Background/aim: Satellitosis/in-transit metastasis (S-ITM) has prognostic value in melanoma and Merkel cell carcinoma, but is not incorporated into cutaneous squamous cell carcinoma (cSCC) staging. Patients And Methods: From our IRB-approved...